A synergistic combination targeting mitochondrial function, cellular energy, and fat metabolism. Combines NAD+ precursor with mitochondrial peptide and NNMT inhibitor for comprehensive metabolic support.
The Triple Threat (NAD+ / MOTS-c / 5-Amino-1MQ) blend is marketed by research suppliers as a synergistic stack for mitochondrial energy, metabolic health, and longevity research. NAD+ replenishes a key redox cofactor, MOTS-c activates AMPK to enhance mitochondrial efficiency and insulin sensitivity, and 5-Amino-1MQ inhibits NNMT to preserve cellular NAD+ and methyl donors.
Combination blend of NAD+ (sirtuin/PARP cofactor supporting cellular energy), MOTS-c (mitochondrial-derived peptide activating AMPK and improving glucose homeostasis), and 5-Amino-1MQ (NNMT inhibitor preserving NAD+ and methyl donors). The three converge on mitochondrial function, cellular energy, and metabolic regulation.
No clinical trials on the combined blend. Component-level safety data is limited. Research use only.
Tesofensine
A serotonin-norepinephrine-dopamine reuptake inhibitor originally studied as an anti-obesity agent. Promotes weight loss through appetite suppression.
0.25-1 mgAnti-Obesity Drug 9604
A synthetic peptide analog of natural AOD-9604 fragment that stimulates lipolysis and inhibits lipogenesis without affecting IGF-1 or insulin.
300 mcg5-Amino-1-Methylquinolinium
A small molecule that inhibits NNMT enzyme, boosting NAD+ levels and cellular energy. Supports fat loss and metabolic function.
1 mgIpamorelin and CJC-1295 without DAC Blend
A powerful synergistic combination of growth hormone secretagogues. Ipamorelin provides selective GH release while CJC-1295 extends GH pulse duration for enhanced fat loss and recovery.
250 mcg each